Cumberland Pharmaceuticals (CPIX) Set to Announce Earnings on Tuesday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Individual interested in registering for the company’s earnings conference call can do so using this link.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%. The firm had revenue of $9.35 million for the quarter.

Cumberland Pharmaceuticals Price Performance

Shares of NASDAQ CPIX opened at $1.53 on Monday. The firm has a market cap of $21.70 million, a P/E ratio of -3.59 and a beta of 0.17. Cumberland Pharmaceuticals has a twelve month low of $1.42 and a twelve month high of $2.36. The company has a quick ratio of 1.11, a current ratio of 1.28 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $1.78 and a 200 day moving average of $1.86.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Thursday. They issued a “hold” rating on the stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.